Stockreport

BioNTech Touts Its Oncology Shift After Reporting Disappointing Fourth Quarter Financials [Yahoo! Finance]

BioNTech SE - American Depositary Shares  (BNTX) 
PDF On Wednesday, BioNTech reported a revenue and earnings drop as it continues its shift towards cancer drug development, much like its peer Pfizer who also turned to oncol [Read more]